Akonni Biosystems and Seegene said this week that they will develop PCR-based tests capable of simultaneously detecting a "wide variety" of pathogens known to cause respiratory disease.
The companies did not disclose the pathogens that would be included in the panel.
The partnership combines Seegene's Dual Priming Oligo multiplex PCR technology with Akonni's TruArray gel-drop microarray technology.
The companies said that the integrated platform should enable "more comprehensive and faster patient diagnosis, more timely delivery of appropriate treatments, a more streamlined workflow including end-to-end sample extraction through detection, and a significant reduction in overall assay and healthcare costs."
The non-exclusive agreement aims to develop both point-of-care and ultra-high throughput diagnostic screening assays, the companies said.
Seegene claims that its DPO technology is ideal for multiple pathogen detection because it is highly specific with no false positives, even for pathogen subtypes with similar genetic background.
Akonni said that its TruArray platform can perform multiplexed analysis of clinical samples and deliver results in 15 minutes for immunoassays or three hours for nucleic acid tests.